Shareholders that lost money on Capricor Therapeutics, Inc.(CAPR) should contact The Gross Law Firm about pending Class Action - CAPR

Core Viewpoint - The Gross Law Firm is notifying shareholders of Capricor Therapeutics, Inc. regarding a potential class action lawsuit due to misleading statements related to the company's lead cell therapy candidate, deramiocel, and its FDA approval process [1][2]. Group 1: Allegations and Impact - Shareholders who purchased shares of Capricor during the class period from October 9, 2024, to July 10, 2025, are encouraged to contact the firm for possible lead plaintiff appointment [1]. - The complaint alleges that Capricor provided investors with misleading information about deramiocel's potential FDA approval while concealing adverse facts from its Phase 2 HOPE-2 trial [1]. - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the Biologics License Application (BLA) due to insufficient evidence of effectiveness, Capricor's stock price fell from $11.40 to $7.64 per share [1]. Group 2: Next Steps for Shareholders - Shareholders are advised to register for the class action by September 15, 2025, to participate in the case without any cost or obligation [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2]. Group 3: Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].